The U.S. Food and Drug Administration on December 17 approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody.
Click HERE to access the press release for more information.
Please ask your doctor is this therapy is right for you.
Note: Medical information included on this website comes from sources that are noted along with the information. Citing a source on this website does not imply an endorsement by Myasthenia Gravis Minnesota, Inc. (mgMN). Always consult your physician, pharmacist, nurse or other health care professional for advice and expertise regarding the care that is best for you.